Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Sets Aside RMB 2.7 Billion To Advance Biopharma Tech

This article was originally published in PharmAsia News

Executive Summary

This year, China’s National Development Reform Commission has earmarked RMB 1.2 billion in funding for projects relating to development of generics and protein biopharma and vaccines.

You may also be interested in...



New China Drug Regulation Legalizes Emergency Approval Mechanism

The first major revision since 2007 notably provides a legal foundation for special approvals under a public health crisis.

3D Carbon Partners With Resolution Medical To Produce More Than 1 Million Nasal Swabs A Week

Resolution Medical teamed up with Carbon to introduce more than one million 3D-printed nasal swabs a week to address the shortage for COVID-19 testing.

ACC 2020: Medtronic’s Evolut TAVR Works In Low-Risk Bicuspid Study

Early results from the Low-Risk Bicuspid study of the Evolut transcatheter aortic valve replacement system showed low rates of all-cause mortality or stroke.

Topics

UsernamePublicRestriction

Register

SC081582

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel